Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2012

View Archived Issues

Cross-strain neutralizing malaria vaccines evaluated in preclinical study

Pathogen-specific R-type pyocin may hold promise to treat EHEC infections

Naturally occurring antiobesity agent mimics calorie restriction in patients with obesity

Phase II study investigates effects of ganetespib in subjects with breast cancer

New metabotropic glutamate mGlu5 receptor antagonists prepared by GlaxoSmithKline

Novel TNF-alpha production inhibitors presented by scientists in China

Novel tyrosine-protein kinase BTK inhibitors disclosed by Ono Pharmaceutical

Dainippon Sumitomo Pharma synthesizes new Toll-like receptor antagonists

New free fatty acid FFA2 receptor agonists/partial agonists reported by Euroscreen

New acetyl-L-carnitine salt prepared in Korea

Bayer Schering Pharma presents new protein kinase inhibitors

Interim data presented from phase I/II trial of neratinib plus capecitabine in breast cancer

Osiris reports on phase II trial of Prochymal

Generex provides update on second-generation peptide vaccine for cancer

Ikaria begins registration trial of bioabsorbable matrix for use after heart attack

SNS01-T shows synergy with lenalidomide in human cancer model

BioMarin's IND for achondroplasia therapy is active

Ampio Pharmaceuticals completes expanded enrollment in Ampion trial

Gene therapy for hemophilia B granted orphan drug status by FDA

Yakult Honsha begins phase I/II study of perifosine in Japan

Phase I/II CF-102 trials meet primary endpoints

MacuCLEAR raises funds and enters partnership for lead AMD treatment

BioMimetic Therapeutics receives response to Augment Bone Graft PMA

FDA approves label expansion for CSL Behring's Berinert

BioMimetic obtains CE mark for growth factor-enhanced matrix

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...
Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis
BioWorld Science
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...